Diagnostic value of CA125 as a predictor of recurrence in advanced ovarian cancer

European Journal of Gynaecological Oncology

Volumn 34, Issue 2, 2013, Pages 148-151

  Song, M J ^a   Lee, S H ^a   Choi, M R ^a   Son, H J ^a   Lee, C W ^a   Yoon, J H ^a   Park, Y G ^a   Hur, S Y ^a   Ryu, K S ^a   Lee, J M ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Advanced ovarian cancer, CA 125; Early detection of recurrence

Indexed keywords

CA 125 ANTIGEN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; COMPARATIVE STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PREDICTOR VARIABLE; SENSITIVITY AND SPECIFICITY;

CA-125 ANTIGEN; FEMALE; HUMANS; LOGISTIC MODELS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84877352166     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Rustin G.J., Bast R.C. Jr., Kelloff G.J., Barrett J.C., Carter S.K., Nisen P.D. et al: "Use of CA125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer". Clin. Cancer Res., 2004, 10, 3919.
2. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A. et al.: "Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study". J. Clin. Oncol., 2003, 21, 3194.
3. Mano M.S., Awada A., Minisini A., Atalay G., Lago L.D., Cardoso F. et al.: "Remaining controversies in the upfront management of advanced ovarian cancer". Int. J. Gynecol. Cancer, 2004, 14, 707.
4. st ed. Edited by Schorge J.O., Schaffer J.I., Halvorson L.M., Hoffman B.L., Bradshaw K.D. and Cunningham F.G. Dallas, TX: The McGraw-Hill Companies, Inc.; 2008, 716.
5. Rustin G.J., van der Burg M.E., Griffin C.L., Guthrie D., Lamont A., Jayson G.C. et al.: "Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial". Lancet, 2010, 376, 1155.
6. Zang R.Y., Li Z.T., Tang J., Cheng X., Cai S.M., Zhang Z.Y. et al.: "Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?". Cancer, 2004, 100, 1152.
7. Chi D.S., McCaughty K., Diaz J.P., Huh J., Schwabenbauer S., Hummer A.J. et al.: "Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma". Cancer, 2006, 106, 1933.
8. Harter P., du Bois A., Hahmann M., Hasenburg A., Burges A., Loibl S. et al.: "Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie(AGO) DESKTOPOVARTrial". Ann. Surg. Oncol., 2006, 13, 1702.
9. nd, Gardner G.J., Armstrong D.K. et al.: "Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome". Cancer, 2007, 109, 685.
10. nd, Gardner G.J., Cass I. et al.: "Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer". Gynecol. Oncol., 2007, 104, 686.
11. Goonewardene T.I., Hall M.R., Rustin G.J.: "Management of asymptomatic patients on follow-up for ovarian cancer with rising CA125 concentrations". Lancet Oncol., 2007, 8, 813.
12. Tuxen M.K., Sölétormos G., Dombernowsky P.: "Serum tumor marker CA125 for monitoring ovarian cancer during follow-up". Scand. J. Clin. Lab. Invest., 2002, 62, 177.
13. Duffy M.J., Bonfrer J.M., Kulpa J., Rustin G.J., Soletormos G., Torre G.C. et al.: "CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use". Int. J. Gynecol. Cancer, 2005, 15, 679.
14. Rustin G.J.: "Use of CA125 to assess response to new agents in ovarian cancer trials". J. Clin. Oncol., 2003, 21, 187.
15. Rustin G.J., Nelstrop A.E., Tuxen M.K., Lambert H.E.: "Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study". Ann. Oncol., 1996, 7, 361.
16. Krebs H.B., Goplerud D.R., Kilpatrick S.J., Myers M.B., Hunt A.: "The role of CA 125 as tumour marker in ovarian cancer". Obstet. Gynecol., 1986, 67, 473.
17. Gronlund B., Lundvall L., Christensen I.J., Knudsen J.B., Høgdall C.: "Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum". Eur. J. Surg. Oncol., 2005, 31, 67.
18. Simcock B., Neesham D., Quinn M., Drummond E., Milner A., Hicks R.J.: "The impact of PET/CT in the management of recurrent ovarian cancer". Gynecol. Oncol., 2006, 103, 271.
19. Crawford S.M., Peace J.: "Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?". Ann. Oncol., 2005, 16, 47.
20. Tuxen M.K., Sölétormos G., Dombernowsky P.: "Serum tumor marker CA125 in monitoring of ovarian cancer during first-line chemotherapy". Br. J. Cancer, 2001, 84, 1301.
21. nd, Armstrong D.K., Bristow R.E.: "Risk of epithelial ovarian cancer recurrence in patients with rising serum CA125 levels within the normal range". J. Clin. Oncol., 2005, 23, 9338.
22. Prat A., Parera M., Adamo B., Peralta S., Perez-Benavente M.A., Garcia A. et al.: "Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA125 levels". Ann. Oncol., 2009, 20, 294.